Inclusion Criteria:

          -  Histological or cytological proof of advanced NSCLC; for PART B: treated with first
             line therapy for metastatic disease only.

          -  Written documentation of a known pathogenic KRAS (exon 2, 3 or 4) mutation and PIK3CA
             wildtype (defined as absence of mutations in exon 9 and 20)

          -  Able and willing to give written informed consent

          -  Able and willing to undergo blood sampling for PK and PD analysis

          -  Life expectancy >=3 months allowing adequate follow up of toxicity evaluation and
             antitumor activity.

          -  WHO performance status of 0 or 1.

          -  Able and willing to undergo a tumor biopsies prior to start, after two weeks (part A
             only) and upon progression of disease

          -  Measurable disease according to RECIST 1.1

          -  Adequate organ system function measured by laboratory values

        Exclusion Criteria:

          -  Any treatment with investigational drugs within 30 days prior to receiving the first
             dose of investigational treatment.

          -  History of another malignancy Exception PART A: Patients who have been disease-free
             for at least 3 years, or patients with a history of completely resected non-melanoma
             skin cancer and/or patients with indolent second malignancies are eligible. Exception
             PART B: Adequately treated carcinoma in situ of the cervix and adequately treated
             basal cell carcinoma of the skin. 3. Symptomatic or untreated leptomeningeal disease.

          -  Symptomatic brain metastasis.

          -  Patients previously treated with any drug combination known to interfere with EGFR,
             HER2, HER3, HER4 or MAPK- and PI3K-pathway components, including inhibitors of PTEN,
             PI3K, AKT, mTOR, BRAF, MEK and ERK.

          -  History of interstitial lung disease or pneumonitis

          -  Radio-, immuno- or chemotherapy within the last 2 weeks prior to receiving the first
             dose of investigational treatment. Palliative radiation (1x 8Gy) is allowed.

          -  Opthalmological diseases

          -  Patients with left ventricular ejection fraction (LVEF) < 55%

          -  Patients with cardiac comorbidities

          -  Concomitant or recent use (in the past 14 days) of strong inhibitors and inducers of
             CYP1A2, CYP2C19, CYP3A4, 3A5 and P-glycoprotein (P-gp)